Picture of Roivant Sciences logo

ROIV — Roivant Sciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Roivant Sciences Ltd reports results for the quarter ended September 30 - Earnings Summary

* Roivant Sciences Ltd  ROIV.OQ  reported a quarterly
adjusted
loss of 31 cents​​ per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -40 cents.  The mean expectation of ten analysts
for the quarter was for a loss of 26 cents per share. Wall
Street expected results to range from -34 cents to -11 cents per
share.
    * Revenue fell 87.9% to $4.48 million from a year ago;
analysts
expected $49.22 million. 
    * Roivant Sciences Ltd's reported EPS for the quarter was a
loss
of 31 cents​.
    * The company reported a quarterly loss of $230.18 million.
    * Roivant Sciences Ltd shares had risen by 2.3% this
quarter and
gained 5.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 9.6%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Roivant Sciences
Ltd is $17.00 
This summary was machine generated from LSEG data November 12 at
01:38 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.26          -0.31          Missed
 Jun. 30 2024      -0.32          0.12           Beat
 Mar. 31 2024      -0.30          -0.19          Beat
 Dec. 31 2023      -0.32          -0.30          Beat

Recent news on Roivant Sciences

See all news